Interleukin-10 and related cytokines and receptors

Annual Review of Immunology

Volumn 22, Issue , 2004, Pages 929-979

  Pestka, Sidney ^a,b,c   Krause, Christopher D ^a   Sarkar, Devanand ^d   Walter, Mark R ^e   Shi, Yufang ^a,c   Fisher, Paul B ^d  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b PBL InterferonSource   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d Columbia University ^*  (United States)

^e University of Alabama at Birmingham   (United States)

Author keywords

Class 2 cytokines; Cytokine evolution; Cytokine structure; Immune regulation; Interferons; Receptor evolution; Receptor structure; Signal transduction

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; CYTOKINE RECEPTOR; DELTA INTERFERON; EPSILON INTERFERON; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 10R1; INTERLEUKIN 10R2; INTERLEUKIN 12; INTERLEUKIN 19; INTERLEUKIN 1BETA; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 24; INTERLEUKIN 26; INTERLEUKIN 28A; INTERLEUKIN 28B; INTERLEUKIN 29; INTERLEUKIN 6; KAPPA INTERFERON; LIMITIN; MEZEREIN; OMEGA INTEFERON; TAU INTERFERON; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGY; AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ASTHMA; CELL GROWTH; CELL LINE; COLITIS; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DNA POLYMORPHISM; DNA SEQUENCE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GENETIC TRANSCRIPTION; HERPES VIRUS SAIMIRI; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; MOLECULAR CLONING; MOLECULAR EVOLUTION; NONHUMAN; NORTHERN BLOTTING; NUCLEAR MAGNETIC RESONANCE; OLIGOMERIZATION; PHYLOGENY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; RECEPTOR AFFINITY; REVIEW; SEQUENCE HOMOLOGY; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION; X RAY;

ANIMALS; CYTOKINES; HUMANS; INTERLEUKIN-10; PHYLOGENY; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY;

EID: 2342659126     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.22.012703.104622     Document Type: Review

References (289)

1. Fiorentino DF, Bond MW, Mosmann TR. 1989. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170:2081-95
2. O'Garra A, Stapleton G, Dhar V, Pearce M, Schumacher J, et al. 1990. Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int. Immunol. 2:821-32
3. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. 1990. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248:1230-34
4. Ding L, Shevach EM. 1992. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J. Immunol. 148:3133-39
5. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, et al. 1991. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146:3444-51
6. Macatonia SE, Doherty TM, Knight SC, O'Garra A. 1993. Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-γ production. J. Immunol. 150:3755-65
7. Enk AH, Angeloni VL, Udey MC, Katz SI. 1993. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J. Immunol. 151:2390-98
8. Peguet-Navarro J, Moulon C, Caux C, Dalbiez-Gauthier C, Banchereau J, Schmitt D. 1994. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. Eur. J. Immunol. 24:884-91
9. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. 1993. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol. 151:1224-34
10. Willems F, Marchant A, Delville JP, Gerard C, Delvaux A, et al. 1994. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur. J. Immunol. 24:1007-9
11. Jinquan T, Larsen CG, Gesser B, Matsushima K, Thestrup-Pedersen K. 1993. Human IL-10 is a chemoattractant for CD8+ T lymphocytes and an inhibitor of IL-8-induced CD4+ T lymphocyte migration. J. Immunol. 151:4545-51
12. Kasama T, Strieter RM, Lukacs NW, Burdick MD, Kunkel SL. 1994. Regulation of neutrophil-derived chemokine expression by IL-10. J. Immunol. 152:3559-69
13. Sozzani S, Ghezzi S, Iannolo G, Luini W, Borsatti A, et al. 1998. Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J. Exp. Med. 187:439-44
14. Takayama T, Morelli AE, Onai N, Hirao M, Matsushima K, et al. 2001. Mammalian and viral IL-10 enhance C-C chemokine receptor 5 but down-regulate C-C chemokine receptor 7 expression by myeloid dendritic cells: impact on chemotactic responses and in vivo homing ability. J. Immunol. 166:7136-43
15. Dokka S, Shi X, Leonard S, Wang L, Castranova V, Rojanasakul Y. 2001. Interleukin-10-mediated inhibition of free radical generation in macrophages. Am. J. Physiol. Lung Cell Mol. Physiol. 280:L1196-202
16. Ishida H, Hastings R, Kearney J, Howard M. 1992. Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1B cells but not conventional B cells. J. Exp. Med. 175:1213-20
17. Levy Y, Brouet JC. 1994. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J. Clin. Invest. 93:424-28
18. Cohen SB, Crawley JB, Kahan MC, Feldmann M, Foxwell BM. 1997. Interleukin-10 rescues T cells from apoptotic cell death: association with an up-regulation of Bcl-2. Immunology 92:1-5
19. Fluckiger AC, Durand I, Banchereau J. 1994. Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells. J. Exp. Med. 179:91-99
20. Cai G, Kastelein RA, Hunter CA. 1999. IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-γ when combined with IL-18. Eur. J. Immunol. 29:2658-65
21. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263-74
22. Yang X, Gartner J, Zhu LH, Wang SH, Brunham RC. 1999. IL-10 gene knockout mice show enhanced Th1-like protective immunity and absent granuloma formation following Chlamydia trachomatis lung infection. J Immunol. 162:1010-17
23. Murray PJ, Young RA. 1999. Increased antimycobacterial immunity in interleukin-10-deficient mice. Infect. Immun. 67:3087-95
24. Sewnath ME, Olszyna DP, Birjmohun R, ten Kate FJ, Gouma DJ, van Der PT. 2001. IL-10-deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J. Immunol. 166:6323-31
25. Vazquez-Torres A, Jones-Carson J, Wagner RD, Warner T, Balish E. 1999. Early resistance of interleukin-10 knockout mice to acute systemic candidiasis. Infect. Immun. 67:670-74
26. Gazzinelli RT, Wysocka M, Hieny S, Scharton-Kersten T, Cheever A, et al. 1996. In the absence of endogenous IL-10, mice acutely infected with toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-γ and TNF-α. J. Immunol. 157:798-805
27. Tournoy KG, Kips JC, Pauwels RA. 2000. Endogenous interleukin-10 suppresses allergen-induced airway inflammation and nonspecific airway responsiveness. Clin. Exp. Allergy 30:775-83
28. Berg DJ, Leach MW, Kuhn R, Rajewsky K, Muller W, et al. 1995. Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses. J. Exp. Med. 182:99-108
29. Grunig G, Corry DB, Leach MW, Seymour BW, Kurup VP, Rennick DM. 1997. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J. Exp. Med. 185:1089-99
30. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. 2003. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18:605-17
31. Hsu DH, de Waal MR, Fiorentino DF, Dang MN, Vieira P, et al. 1990. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 250:830-32
32. Rode HJ, Janssen W, Rosen-Wolff A, Bugert JJ, Thein P, et al. 1993. The genome of equine herpesvirus type 2 harbors an interleukin 10 (IL10)-like gene. Virus Genes 7:111-16
33. Rivailler P, Jiang H, Cho YG, Quink C, Wang F. 2002. Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-Barr virus animal model. J. Virol. 76:421-16
34. Rivailler P, Cho YG, Wang F. 2002. Complete genomic sequence of an Epstein-Barr virus-related herpesvirus naturally infecting a New World primate: a defining point in the evolution of oncogenic lymphocryptoviruses. J. Virol. 76:12055-68
35. Fleming SB, McCaughan CA, Andrews AE, Nash AD, Mercer AA. 1997. A homolog of interleukin-10 is encoded by the poxvirus orf virus. J. Virol. 71:4857-61
36. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S. 2000. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc. Natl. Acad. Sci. USA 97:1695-700
37. Lockridge KM, Zhou SS, Kravitz RH, Johnson JL, Sawai ET, et al. 2000. Primate cytomegaloviruses encode and express an IL-10-like protein. Virology 268:272-80
38. Hughes AL. 2002. Origin and evolution of viral interleukin-10 and other DNA virus genes with vertebrate homologues. J. Mol. Evol. 54:90-101
39. Fleming SB, Haig DM, Nettleton P, Reid HW, McCaughan CA, et al. 2000. Sequence and functional analysis of a homolog of interleukin-10 encoded by the parapoxvirus orf virus. Virus Genes 21:85-95
40. Haig DM, Thomson J, McInnes CJ, Deane DL, Anderson IE, et al. 2002. A comparison of the anti-inflammatory and immuno-stimulatory activities of orf virus and ovine interleukin-10. Virus Res. 90:303-16
41. Stewart JP, Behm FG, Arrand JR, Rooney CM. 1994. Differential expression of viral and human interleukin-10 (IL-10) by primary B cell tumors and B cell lines. Virology 200:724-32
42. Touitou R, Cochet C, Joab I. 1996. Transcriptional analysis of the Epstein-Barr virus interleukin-10 homologue during the lytic cycle. J. Gen. Virol. 77(Pt. 6):1163-68
43. Moore KW, de Waal MR, Coffman RL, O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683-765
44. Zou J, Clark MS, Secombes CJ. 2003. Characterisation, expression and promoter analysis of an interleukin 10 homologue in the puffer fish, Fugu rubripes. Immunogenetics 55:325-35
45. Kotenko SV. 2002. The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev. 13:223-40
46. Brewer G, Saccani S, Sarkar S, Lewis A, Pestka S. 2003. Increased interleukin-10 mRNA stability in melanoma cells is associated with decreased levels of A + U-rich element binding factor AUF1. J. Interferon Cytokine Res. 23:553-64
47. Lutfalla G, Gardiner K, Proudhon D, Vielh E, Uze G. 1992. The structure of the human interferon αlβ receptor gene. J. Biol. Chem. 267:2802-9
48. Bach EA, Tanner JW, Marsters S, Ashkenazi A, Aguet M, et al. 1996. Ligand-induced assembly and activation of the γ interferon receptor in intact cells. Mol. Cell Biol. 16:3214-21
49. Novick D, Cohen B, Rubinstein M. 1992. Soluble interferon-α receptor molecules are present in body fluids. FEBS Lett. 314:445-48
50. Domanski P, Witte M, Kellum M, Rubinstein M, Hackett R, et al. 1995. Cloning and expression of a long form of the β subunit of the interferon α β receptor that is required for signaling. J. Biol. Chem. 270:21606-11
51. Usacheva A, Kotenko S, Witte MM, Colamonici OR. 2002. Two distinct domains within the N-terminal region of Janus kinase 1 interact with cytokine receptors. J. Immunol. 169:1302-8
52. Usacheva A, Sandoval R, Domanski P, Kotenko SV, Nelms K, et al. 2002. Contribution of the Box 1 and Box 2 motifs of cytokine receptors to Jak1 association and activation. J. Biol. Chem. 277:48220-26
53. Abramovich C, Ratovitski E, Lundgren E, Revel M. 1994. Identification of mRNAs encoding two different soluble forms of the human interferon α-receptor. FEBS Lett. 338:295-300
54. Cook JR, Cleary CM, Mariano TM, Izotova L, Pestka S. 1996. Differential responsiveness of a splice variant of the human type I interferon receptor to interferons. J. Biol. Chem. 271:13448-53
55. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, et al. 2003. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4:69-77
56. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, et al. 2003, IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4:63-68
57. Krause CD, Mei E, Xie J, Jia Y, Bopp MA, et al. 2002. Seeing the light: preassembly and ligand-induced changes of the interferon γ receptor complex in cells. Mol. Cell Proteomics 1:805-15
58. Kotenko SV, Izotova LS, Pollack BP, Muthukumaran G, Paukku K, Silvennoinen O, et al. 1996. Other kinases can substitute for Jak2 in signal transduction by interferon-γ. J. Biol. Chem. 271:17174-82
59. Finbloom DS, Winestock KD. 1995. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J. Immunol. 155:1079-90
60. Weber-Nordt RM, Riley JK, Greenlund AC, Moore KW, Darnell JE, Schreiber RD. 1996. Stat3 recruitment by two distinct ligand-induced, tyrosine- phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J. Biol. Chem. 271:27954-61
61. Wehinger J, Gouilleux F, Groner B, Finke J, Mertelsmann R, Weber-Nordt RM. 1996. IL-10 induces DNA binding activity of three STAT proteins (Stal1, Stat3, and Stat3) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett. 394:365-70
62. Ding Y, Chen D, Tarcsafalvi A, Su R, Qin L, Bromberg JS. 2003. Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. J. Immunol 170:1383-91
63. Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, et al. 1999. SOCS1 is a critical inhibitor of interferon γ signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98:597-608
64. Naka T, Tsutsui H, Fujimoto M, Kawazoe Y, Kohzaki H, et al. 2001. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-γ and IL-4 signaling in vivo. Immunity 14:535-45
65. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, et al. 1999. The JAK-binding protein JAB inhibits janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18:1309-20
66. Kamura T, Sato S, Haque D, Liu L, Kaelin WG, et al. 1998. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 12:3872-81
67. Zhang JG, Farley A, Nicholson SE, Willson TA, Zugaro LM, et al. 1999. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. USA 96:2071-76
68. Hanada T, Yoshida T, Kinjyo I, Minoguchi S, Yasukawa H, et al. 2001. A mutant form of JAB/SOCS1 augments the cytokine-induced JAK/STAT pathway by accelerating degradation of wild-type JAB/CIS family proteins through the SOCS-box. J. Biol. Chem. 276:40746-54
69. Niemand C, Nimmesgern A, Haan S, Fischer P, Schaper F, et al. 2003. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J. Immunol. 170:3263-72
70. Shames BD, Selzman CH, Meldrum DR, Pulido EJ, Barton HA Jr, et al. 1998. Interleukin-10 stabilizes inhibitory κB-α in human monocytes. Shock 10:389-94
71. Wang P, Wu P, Siegel M, Egan RW, Billah MM. 1995. Interleukin (IL)-10 inhibits nuclear factor κ B (NFκB) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J. Biol Chem. 270: 9558-63
72. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr. 1999. Interleukin-10 signaling blocks inhibitor of κB kinase activity and nuclear factor κB DNA binding. J. Biol. Chem. 274:31868-74
73. Wang M, Hu Y, Stearns ME. 2003. A novel IL-10 signalling mechanism regulates TIMP-1 expression in human prostate tumour cells. Br. J. Cancer 88:1605-14
74. Stearns ME, Hu Y, Wang M. 2003. IL-10 signaling via IL-10E1 is dependent on tyrosine phosphorylation in the IL-10Rα chain in human primary prostate cancer cell lines. Oncogene 22:3781-91
75. Shuai K, Schindler C, Prezioso VR, Darnell JE Jr. 1992. Activation of transcription by IFN-γ: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 258:1808-12
76. Ramana CV, Grammatikakis N, Chernov M, Nguyen H, Goh KC, et al. 2000. Regulation of c-myc expression by IFN-γ through Stat1-dependent and -independent pathways. EMBO J. 19:263-72
77. Ramana CV, Gil MP, Han Y, Ransohoff RM, Schreiber RD, Stark GR. 2001. Stat1-independent regulation of gene expression in response to IFN-γ. Proc. Natl. Acad. Sci. USA 98:6674-79
78. Gil MP, Bohn E, O'Guin AK, Ramana CV, Levine B, et al. 2001. Biologic consequences of Stat1-independent IFN signaling. Proc. Natl. Acad. Sci. USA 98:6680-85
79. Riley JK, Takeda K, Akira S, Schreiber RD. 1999. Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J. Biol. Chem. 274:16513-21
80. Vigano P, Somigliana E, Mangioni S, Vignali M, Vignali M, Di Blasio AM. 2002. Expression of interleukin-10 and its receptor is up-regulated in early pregnant versus cycling human endometrium. J. Clin. Endocrinol. Metab. 87:5730-36
81. Ng SC, Gilman-Sachs A, Thaker P, Beaman KD, Beer AE, Kwak-Kim J. 2002. Expression of intracellular Th1 and Th2 cytokines in women with recurrent spontaneous abortion, implantation failures after IVF/ET or normal pregnancy. Am. J. Reprod. Immunol. 48:77-86
82. Orange S, Horvath J, Hennessy A. 2003. Preeclampsia is associated with a reduced interleukin-10 production from peripheral blood mononuclear cells. Hypertens. Pregnancy 22:1-8
83. Nagaeva O, Jonsson L, Mincheva-Nilsson L. 2002. Dominant IL-10 and TGF-β mRNA expression in γδT cells of human early pregnancy decidua suggests immunoregulatory potential. Am. J. Reprod. Immunol. 48:9-17
84. Heikkinen J, Mottonen M, Komi J, Alanen A, Lassila O. 2003. Phenotypic characterization of human decidual macrophages. Clin. Exp. Immunol. 131:498-505
85. Moreau P, Adrian-Cabestre F, Menier C, Guiard V, Gourand L, et al. 1999. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int. Immunol. 11:803-11
86. Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, et al. 2002. Human CD25+CD4+ T suppressor cell clones produce transforming growth factor β, but not interleukin 10, and are distinct from type 1 T regulatory cells. J. Exp. Med. 196:1335-46
87. de Kleer IM, Kamphuis SM, Rijkers GT, Scholtens L, Gordon G, et al. 2003. The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30+ T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10. Arthritis Rheum. 48:2001-10
88. Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, et al. 2001. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J. Immunol. 166:3789-96
89. Ke Y, Kapp LM, Kapp JA. 2003. Inhibition of tumor rejection by γδT cells and IL-10. Cell Immunol. 221:107-14
90. Seymour BW, Friebertshauser KE, Peake JL, Pinkerton KE, Coffman RL, Gershwin LJ. 2002. Gender differences in the allergic response of mice neonatally exposed to environmental tobacco smoke. Dev. Immunol. 9(1):47-54
91. Wilder RL. 1998. Hormones, pregnancy, and autoimmune diseases. Ann. NY Acad. Sci. 840:45-50
92. Dalal M, Kim S, Voskuhl RR. 1997. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J. Immunol. 159:3-6
93. Liva SM, Voskuhl RR. 2001. Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production. J. Immunol. 167:2060-67
94. Kimball AB, Kawamura T, Tejura K, Boss C, Hancox AR, et al. 2002. Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. Arch. Dermatol. 138:1341-46
95. Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJ, et al. 2002. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ. Gut 50:191-95
96. Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, et al. 1995. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med. 181:839-44
97. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. 1998. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin. Exp. Rheumatol. 16:283-88
98. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. 1994. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179:305-10
99. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, et al. 2000. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43:1790-800
100. Isaacs A, Lindenmann J. 1957. Virus interference: I. The interferon. Proc. R. Soc. London Ser. B 147:258-67
101. Pestka S, Langer JA, Zoon KC, Samuel CE. 1987. Interferons and their actions. Annu. Rev. Biochem. 56:727-77
102. Pestka S. 1981. Cloning of human interferons. In Methods in Enzymology, ed. S Pestka, pp. 599-601. New York: Academic
103. Pestka S. 1986. Interferon from 1981 to 1986. In Methods in Enzymology, ed. S Pestka, pp. 3-14. New York: Academic
104. Lefevre F, Guillomot M, D'Andrea S, Battegay S, La Bonnardiere C. 1998. Interferon-δ: the first member of a novel type I interferon family. Biochimie 80:779-88
105. Roberts RM, Cross JC, Leaman DW. 1991. Unique features of the trophoblast interferons. Pharmacol. Ther. 51:329-45
106. Oritani K, Medina KL, Tomiyama Y, Ishikawa J, Okajima Y, et al. 2000. Limitin: an interferon-like cytokine that preferentially influences B-lymphocyte precursors. Nat. Med. 6:659-66
107. LaFleur DW, Nardelli B, Tsareva T, Mather D, Feng P, et al. 2001. Interferon-κ, a novel type I interferon expressed in human keratinocytes. J. Biol. Chem. 276:39765-71
108. Chen J, Wood WI. 2003. Patent No. 6,300,475
109. Hardy MP, Owczarek CM, Jermiin L, Ejdebäck M, Hertzog PJ. 2004. Characterization of the type I interferon locus and identification of novel genes. Genomics. In press
110. Cross JC, Farin CE, Sharif SF, Roberts SM. 1990. Characterization of the antiviral activity constitutively produced by murine conceptuses: Absence of placental mRNAs for interferon alpha and beta. Mol. Reprod. Dev. 26:122-28
111. Bakhutashvili VI, Merabishvili DG, Gogitashvili RV, Korsantiia BM, Dzotsenidze LL. 1985. Physicochemical and biological properties of human placental amniotic interferon. Vopr. Virusol. 30:693-97 (In Russian)
112. Duc-Gorran P, Chany C, Doly J. 1989. Unusually large interferon-alpha- like mRNAs and high expression of interleukin-6 in human fetal annexes. J. Biol. Chem. 264:16507-11
113. Duc-Goiran P, Lebon P, Chany C. 1986. Measurement of interferon in human amniotic fluid and placental blood extract. Methods Enzymol. 119:541-51
114. Pestka S. 1983. The human interferons-from protein purification and sequence to cloning and expression in bacteria: before, between, and beyond. Arch. Biochem. Biophys. 221:1-37
115. Pestka S. 2000. The human interferon a species and receptors. Biopolymers 55:254-87
116. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. 1998. How cells respond to interferons. Annu. Rev. Biochem. 67:227-64
117. Berg K. 1982. Purification and characterization of murine and human interferons. A review of the literature of the 1970s. Acta Pathol. Microbiol. Immunol. Scand. Suppl. 279:1-136
118. Rubinstein M, Rubinstein S, Familletti PC, Miller RS, Waldman AA. 1978. Human leukocyte interferon purified to homogeneity. Science 202:1289-90
119. Rubinstein M, Rubinstein S, Familletti PC, Miller RS, Waldman AA, Pestka S. 1979. Human leukocyte interferon: production, purification to homogeneity, and initial characterization. Proc. Natl. Acad. Sci. USA 76:640-44
120. Rubinstein M, Levy WP, Moschera JA, Lai C-Y, Hershberg RD, et al. 1981. Human leukocyte interferon: isolation and characterization of several molecular forms. Arch. Biochem. Biophys. 210:307-18
121. Stein S, Kenny C, Friesen HJ, Shively J, Del Valle U, Pestka S. 1980. NH2-terminal amino acid sequence of human fibroblast interferon. Proc. Natl. Acad. Sci. USA 77:5716-19
122. Friesen HJ, Stein S, Pestka S. 1981. Purification of human. Fibroblast interferon by high-performance liquid chromatography. See Ref. 100, pp. 430-35
123. Evinger M, Rubinstein M, Pestka S. 1981. Antiproliferative and antiviral activities of human leukocyte interferons. Arch. Biochem. Biophys. 210:319-29
124. Maeda S, McCandliss R, Gross M, Sloma A, Familletti PC, et al. 1980. Construction and identification of bacterial plasmids containing nucleotide sequence for human leukocyte interferon. Proc. Natl. Acad. Sci. USA 77:7010-13
125. Goeddel DV, Pestka S. 1989. U.S. Patent No. 4,801,685
126. Henco K, Brosius J, Fujisawa A, Fujisawa J-I, Haynes JR, et al. 1985. Structural relationship of human interferon alpha genes and pseudogenes. J. Mol. Biol. 185:227-60
127. Pestka S. 1997. The human interferon alpha species and hybrid proteins. Semin. Oncol. 24(Suppl. 9):S9-4-9-17
128. Pestka S. 1998. U.S. Patent No. 5,789, 551
129. Pestka S. 1999. U.S. Patent No. 5,869, 293
130. Pestka S. 1999. U.S. Patent No. 6,001, 589
131. Pestka S. 2001. U.S. Patent No. 6,299, 870
132. Pestka S. 2001. U.S. Patent No. 6,300, 474
133. Ortaldo JR, Herberman RB, Harvey C, Osheroff P, Pan YC, et al. 1984. A species of human α interferon that lacks the ability to boost human natural killer activity. Proc. Natl. Acad. Sci. USA 81:4926-29
134. Pestka S. 1997. The interferon receptors. Semin. Oncol. 24(Suppl. 9):S9-18-9-40
135. Pestka S, Kotenko SV, Muthukumaran G, Izotova LS, Cook JR, Garotta G. 1997. The interferon γ (IFN-γ) receptor: a paradigm for the multichain cytokine receptor. Cytokine Growth Factor Rev. 8:189-206
136. Darnell JE Jr. 1997. STATs and gene regulation. Science 277:1630-35
137. Fu XY, Schindler C, Improta T, Aebersold R, Darnell JE Jr. 1992. The proteins of ISGF-3, the interferon α-induced transcriptional activator, define a gene family involved in signal transduction. Proc. Natl. Acad. Sci. USA 89:7840-43
138. Ortaldo JR, Mason A, Rehberg E, Moschera J, Kelder B, et al. 1983. Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J. Biol. Chem. 258:15011-15
139. Ortaldo JR, Mantovani A, Hobbs D, Rubinstein M, Pestka S, Herberman RB. 1983. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int. J. Cancer 31:285-89
140. Rehberg E, Kelder B, Hoal EG, Pestka S. 1982. Specific molecular activities of recombinant and hybrid leukocyte interferons. J. Biol. Chem. 257:11497-502
141. Herberman RB, Ortaldo JR, Mantovani A, Hobbs DS, Kung H-F, Pestka S. 1982. Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol. 67:160-67
142. Ortaldo JR, Herberman RB, Pestka S. 1982. Augmentation of human natural killer cells with human leukocyte and human recombinant leukocyte interferon. In NK Cells and Other Natural Effector Cells, ed. RB Herberman, pp. 1279-83. New York: Academic
143. Ortaldo JR, Mason A, Rehberg E, Kelder B, Harvey C, et al. 1983. Augmentation of NK activity with recombinant and hybrid recombinant human leukocyte interferons. In The Biology of the Interferon System, ed. E De Maeyer, H Schellekens, pp. 353-58. Amsterdam: Elsevier Sci.
144. Greiner JW, Hand PH, Noguchi P, Fisher PB, Pestka S, Schlom J. 1984. Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte α-interferon treatment. Cancer Res. 44:3208-14
145. Greiner JW, Schlom J, Pestka S, Langer JA, Giacomini P, et al. 1985. Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons. Pharmacol. Ther. 31:209-36
146. Greiner JW, Guadagni F, Noguchi P, Pestka S, Colcher D, et al. 1987. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 235:895-98
147. Basham TY, Bourgeade MF, Creasey AA, Merigan TC. 1982. Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines. Proc. Natl. Acad. Sci. USA 79:3265-69
148. Dolei A, Capobianchi MR, Ameglio F. 1983. Human interferon-γ enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than interferon-α and interferon-β. Infect. Immun. 40:172-76
149. Clemens MJ. 2003. Interferons and apoptosis. J. Interferon Cytokine Res. 23:277-92
150. Keay S, Grossberg SE. 1980. Interferon inhibits the conversion of 3T3-L1 mouse fibroblasts into adipocytes. Proc. Natl. Acad. Sci. USA 77:4099-103
151. Fisher PB, Hermo H Jr, Prignoli DR, Weinstein IB, Pestka S. 1984. Hybrid recombinant human leukocyte interferon inhibits differentiation in murine B-16 melanoma cells. Biochem. Biophys. Res. Commun. 119:108-15
152. Fisher PB, Prignoli DR, Hermo H Jr, Weinstein IB, Pestka S. 1985. Effects of combined treatment with interferon and mezerein on melanogenesis and growth in human melanoma cells. J. Interferon Res. 5:11-22
153. Fidler IJ. 2001. Regulation of neoplastic angiogenesis. J. Natl. Cancer Inst. Monogr. 28:10-14
154. Kerbel R, Folkman J. 2002. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2:727-39
155. Gallagher G, Dickensheets H, Eskdale J, Izotova LS, Mirochnitchenko OV, et al. 2000. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun. 1:442-50
156. Chang C, Magracheva E, Kozlov S, Fong S, Tobin G, et al. 2003. Crystal structure of interleukin-19 defines a new subfamily of helical cytokines. J. Biol. Chem. 278:3308-13
157. Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. 2002. IL-19 induces production of IL-6 and TNF-α and results in cell apoptosis through TNF-α. J. Immunol. 169:4288-97
158. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC. 2001. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J. Immunol. 167:3545-49
159. Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, et al. 2002. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J. Biol. Chem. 277:47517-23
160. Wolk K, Kunz S, Asadullah K, Sabat R. 2002, Cutting edge: immune cells as sources and targets of the IL-10 family members? J. Immunol. 168:5397-402
161. Nestle FO, Turka LA, Nickoloff BJ. 1994. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J. Clin. Invest. 94:202-9
162. Rocken M, Urban J, Shevach EM. 1994. Antigen-specific activation, tolerization, and reactivation of the interleukin 4 pathway in vivo. J. Exp. Med. 179:1885-93
163. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, et al. 2003. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9:40-46
164. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, et al. 2001. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104:9-19
165. Rich BE. 2003. IL-20: a new target for the treatment of inflammatory skin disease. Expert Opin. Ther. Targets 7:165-74
166. Dumoutier L, Louahed J, Renauld JC. 2000. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J. Immunol. 164:1814-19
167. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. 1995. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 11:2477-86
168. Knappe A, Hor S, Wittmann S, Fickenscher H. 2000. Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J. Virol. 74:3881-17
169. Dumoutier L, Van Roost E, Colau D, Renauld JC. 2000. Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc. Natl. Acad. Sci. USA 97: 10144-49
170. Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, et al. 2000. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J. Biol. Chem. 275:31335-39
171. Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, et al. 2001. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (TL-10Rβ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J. Biol. Chem. 276:2725-32
172. Pittmann DD, Goad B, Lambert AJ, Clark E, Tan XY, Spaulding V, et al.
173. Wei CC, Ho TW, Liang WG, Chen GY, Chang MS. 2003. Cloning and characterization of mouse IL-22 binding protein. Genes Immun. 4:204-11
174. Levitt RC, McLane MP, MacDonald D, Ferrante V, Weiss C, et al. 1999. IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. J. Allergy Clin. Immunol. 103:S485-91
175. McLane MP, Haczku A, van de Rijn M, Weiss C, Ferrante V, MacDonald D, et al. 1998. Interleukin-9 promotes allergen-induced eosinophilic inflammation and airway hyperresponsiveness in transgenic mice. Am. J. Respir. Cell Mol. Biol. 19:713-20
176. Cookson W. 1999. The alliance of genes and environment in asthma and allergy. Nature 402:B5-11
177. Barnes KC, Neely JD, Duffy DL, Freidhoff LR, Breazeale DR, et al. 1996. Linkage of asthma and total serum IgE concentration to markers on chromosome 12q: evidence from Afro-Caribbean and Caucasian populations. Genomics 37:41-50
178. Nickel R, Wahn U, Hizawa N, Maestri N, Duffy DL, et al. 1997. Evidence for linkage of chromosome 12q15-q24.1 markers to high total serum IgE concentrations in children of the German Multicenter Allergy Study. Genomics 46:159-62
179. Barnes KC, Freidhoff LR, Nickel R, Chiu YF, Juo SH, et al. 1999. Dense mapping of chromosome 12q13.12-q23.3 and linkage to asthma and atopy. J. Allergy Clin. Immunol. 104:485-91
180. Wilkinson J, Thomas NS, Morton N, Holgate ST. 1999. Candidate gene and mutational analysis in asthma and atopy. Int. Arch. Allergy Immunol. 118:265-67
181. Hayden C, Pereira E, Rye P, Palmer L, Gibson N, et al. 1997. Mutation screening of interferon-gamma (TFNgamma) as a candidate gene for asthma. Clin. Exp. Allergy 27:1412-16
182. Kotenko SV, Krause CD, Izotova LS, Pollack BP, Wu W, Pestka S. 1997. Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J. 16:5894-903
183. Liu Y, Wei SH, Ho AS, de Waal MR, Moore KW 1994. Expression cloning and characterization of a human IL-10 receptor. J. Immunol. 152:1821-29
184. Kotenko SV, Pestka S. 2000. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 19:2557-65
185. Dumoutier L, Lejeune D, Colau D, Renauld JC. 2001. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J. Immunol. 166:7090-95
186. Kotenko SV, Izotova LS, Mirochnitchenko OV, Lee C, Pestka S. 1999. The intracellular domain of interferon-α receptor 2c (IFN-αR2c) chain is responsible for Stat activation. Proc. Natl. Acad. Sci. USA 96:5007-12
187. Wang M, Tan Z, Zhang R, Kotenko SV, Liang P, 2002. Interleukin 24 (MDA-7/MOB-5) signals through two heterodimeric receptors, IL-22R1/TL-20R2 and IL-20R1/TL-20R2. J. Biol. Chem. 277:7341-47
188. Zhang R, Tan Z, Liang P. 2000. Identification of a novel ligand-receptor pair constitutively activated by ras oncogenes. J. Biol. Chem. 275:24436-43
189. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, et al. 1999. Stat3 as an oncogene. Cell 98:295-303
190. Gruenberg BH, Schoenemeyer A, Weiss B, Toschi L, Kunz S, et al. 2001. A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta. Genes Immun. 2:329-34
191. Xu W, Presnell SR, Parrish-Novak J, Kindsvogel W, Jaspers S, et al. 2001. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc. Natl. Acad. Sci. USA 98:9511-16
192. Lutfalla G, Holland SJ, Cinato E, Monneron D, Reboul J, et al. 1995. Mutant U5A cells are complemented by an interferon-α β receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J. 14:5100-8
193. Novick D, Cohen B, Rubinstein M. 1994. The human interferon α/β receptor: characterization and molecular cloning. Cell 77:391-400
194. Pfeffer LM, Basu L, Pfeffer SR, Yang CH, Murti A, et al. 1997. The short form of the interferon α/β receptor chain 2 acts as a dominant negative for type I interferon action. J. Biol. Chem. 272: 11002-5
195. Hardy MP, Owczarek CM, Trajanovska S, Liu X, Kola I, Hertzog PJ. 2001, The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood 97:473-82
196. Reboul J, Gardiner K, Monneron D, Uze G, Lutfalla G. 1999. Comparative genomic analysis of the interferon/interleukin-10 receptor gene cluster. Genome Res. 9:242-50
197. Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, et al. 2001. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene 20:7051-63
198. Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, Sahin AA, Read CM, et al. 2001. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int. J. Cancer 94:54-59
199. Madireddi MT, Dent P, Fisher PB. 2000. Regulation of mda-7 gene expression during human melanoma differentiation. Oncogene 19:1362-68
200. Madireddi MT, Dent P, Fisher PB. 2000. AP-1 and C/EBP transcription factors contribute to mda-7 gene promoter activity during human melanoma differentiation. J. Cell Physiol. 185:36-46
201. Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, et al. 2002. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J. Immunol. 168:6041-46
202. Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB. 1996. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc. Natl. Acad. Sci. USA 93: 9160-65
203. Madireddi MT, Su ZZ, Young CS, Goldstein NI, Fisher PB. 2000. Mda-7, a novel melanoma differentiation associated gene with promise for cancer gene therapy. Adv. Exp. Med. Biol. 465:239-61
204. Mhashilkar AM, Schrock RD, Hindi M, Liao J, Sieger K, et al. 2001. Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy. Mol. Med. 7:271-82
205. Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, et al. 2002, mda-7 (IL-24): signaling and functional roles. BioTechniques (Suppl.), pp. 30-39
206. Soo C, Shaw WW, Freymiller E, Longaker MT, Bertolami CN, et al. 1999. Cutaneous rat wounds express c49a, a novel gene with homology to the human melanoma differentiation associated gene, mda-7. J. Cell Biochem. 74:1-10
207. Schaefer G, Venkataraman C, Schindler U. 2001. Cutting edge: FISP (IL-4-induced secreted protein), a novel cytokine-like molecule secreted by Th2 cells. J. Immunol. 166:5859-63
208. Garn H, Schmidt A, Grau V, Stumpf S, Kaufmann A, et al. 2002. IL-24 is expressed by rat and human macrophages. Immunobiology 205:321-34
209. Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, et al. 2002. Loss of MDA-7 expression with progression of melanoma. J. Clin. Oncol. 20:1069-74
210. Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Lebedeva IV, et al. 2003. MDA-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev. 14:35-51
211. Su ZZ, Lebedeva IV, Sarkar D, Gopalkrishnan RV, Sauane M, et al. 2003. Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene 22:1164-80
212. Su ZZ, Lebedeva IV, Gopalkrishnan RV, Goldstein NI, Stein CA, et al. 2001. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc. Natl. Acad. Sci. USA 98:10332-37
213. Lebedeva IV, Su ZZ, Chang Y, Kitada S, Reed JC, Fisher PB. 2002. The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene 21:708-18
214. Lebedeva IV, Sarkar D, Su ZZ, Kitada S, Dent P, et al. 2003. Bcl-2 and Bcl-xL differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene. 22:8758-73
215. Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, et al. 2002. mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc. Natl. Acad. Sci. USA 99:10054-59
216. Pataer A, Vorburger SA, Barber GN, Chada S, Mhashilkar AM, et al. 2002. Adenoviral transfer of the melanoma differentiation-associated gene 7 (mda7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR). Cancer Res. 62:2239-43
217. Ekmekcioglu S, Ellerhorst JA, Mumm JB, Zheng M, Broemeling L, et al. 2003. Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. Mol. Cancer Ther. 2:9-17
218. Saeki T, Mhashilkar A, Swanson X, Zou-Yang XH, Sieger K, et al. 2002. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene 21: 4558-66
219. Sauane M, Gopalkrishnan RV, Lebedeva I, Mei MX, Sarkar D, et al. 2003. mda-7/IL-24 induces apoptosis of diverse cancer cell lines through JAK/STAT-independent pathways. J. Cell Physiol. 196:334-45
220. Goris A, Marrosu MG, Vandenbroeck K. 2001. Novel polymorphisms in the IL-10 related AK155 gene (chromosome 12q15). Genes Immun. 2:284-86
221. Lutfalla G, Crollius HR, Stange-Thomann N, Jaillon O, Mogensen K, Monneron D. 2003. Comparative genomic analysis reveals independent expansion of a lineage-specific gene family in vertebrates: the class II cytokine receptors and their ligands in mammals and fish. BMC Genomics 4:29
222. Radhakrishnan R, Walter LJ, Subramaniam PS, Johnson HM, Walter MR. 1999. Crystal structure of ovine interferon-τ at 2.1 Å resolution. J. Mol. Biol. 286:151-62
223. Karpusas M, Nolte M, Benton CB, Meier W, Lipscomb WN, Goelz S. 1997. The crystal structure of human interferon β at 2.2-Å resolution. Proc. Natl. Acad. Sci. USA 94:11813-18
224. Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, et al. 1996. Zinc mediated dimer of human interferon-α2b revealed by X-ray crystallography. Structure 4:1453-63
225. Ealick SE, Cook WJ, Vijay-Kumar S, Carson M, Nagabhushan TL, et al. 1990. Three dimensional structure of recombinant human interferon-γ. Science 252:698-702
226. Deleted in proof
227. Walter MR, Windsor WT, Nagabhushan TL, Lundell DJ, Lunn CA, et al. 1995. Crystal structure of a complex between interferon-γ and its soluble high-affinity receptor. Nature 376:230-35
228. Randal M, Kossiakoff AA. 2000. The 2.0 Å structure of bovine interferon-γ; assessment of the structural differences between species. Acta Crystallogr. D 56 (Pt. 1):14-24
229. Thiel DJ, le Du MH, Walter RL, D'Arcy A, Chene C, et al. 2000. Observation of an unexpected third receptor molecule in the crystal structure of human interferon-γ receptor complex. Structure 8:927-36
230. Randal M, Kossiakoff AA. 2001. The structure and activity of a monomeric interferon-γ:α-chain receptor signaling complex. Structure 9:155-63
231. Zdanov A, Schalk-Hihi C, Gustchina A, Tsang M, Weatherbee J, Wlodawer A. 1995. Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon γ. Structure 3:591-601
232. Walter MR, Nagabhushan TL. 1995. Crystal structure of interleukin 10 reveals an interferon gamma-like fold. Biochemistry 34:12118-25
233. Nagem RA, Colau D, Dumoutier L, Renauld JC, Ogata C, Polikarpov I. 2002. Crystal structure of recombinant human interleukin-22. Structure 10:1051-62
234. Deleted in proof
235. de Vos AM, Ultsch M, Kossiakoff AA. 1992. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255:306-12
236. Josephson K, Logsdon NJ, Walter MR. 2001. Crystal structure of the JL-10/IL-10R1 complex reveals a shared receptor binding site. Immunity 15:35-46
237. Chill JH, Quadt SR, Levy R, Schreiber G, Anglister J. 2003. The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding. Structure 11:791-802
238. Deleted in proof
239. Deleted in proof
240. Deleted in proof
241. Moyle WR, Campbell RK, Myers RV, Bernard MP, Han Y, Wang X. 1994. Co-evolution of ligand-receptor pairs. Nature 368:251-55
242. Koretke KK, Lupas AN, Warren PV, Rosenberg M, Brown JR. 2000. Evolution of two-component signal transduction. Mol. Biol. Evol. 17:1956-70
243. Deleted in proof
244. Altmann SM, Mellon MT, Distel DL, Kim CH. 2003. Molecular and functional analysis of an interferon gene from the zebrafish, Danio rerio. J. Virol. 77:1992-2002
245. Goldman LA, Cutrone EC, Dang A, Hao X, Lim JK, Langer JA. 1998. Mapping human interferon-α (IFN-α2) binding determinants of the type I interferon receptor subunit IFNAR-1 with human/bovine IFNAR-1 chimeras. Biochemistry 37:13003-10
246. Cutrone EC, Langer JA. 2001. Identification of critical residues in bovine IFNAR-1 responsible for interferon binding. J. Biol. Chem. 276:17140-48
247. Abdel-Meguid SS, Shieh HS, Smith WW, Dayringer HE, Violand BN, Bentle LA. 1987. Three-dimensional structure of a genetically engineered variant of porcine growth hormone. Proc. Natl. Acad. Sci. USA 84:6434-37
248. Piehler J, Schreiber G. 1999. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2. J. Mol. Biol. 294:223-37
249. Piehler J, Roisman LC, Schreiber G. 2000. New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface. J. Biol. Chem. 275:40425-33
250. Runkel L, deDios C, Karpusas M, Betzenhauser M, Muldowney C, et al. 2000. Systematic mutational mapping of sites on human interferon-β-1a that are important for receptor binding and functional activity. Biochemistry 39:2538-51
251. Bennett MJ, Schlunegger MP, Eisenberg D. 1995. 3D domain swapping: a mechanism for oligomer assembly. Protein Sci. 4:2455-68
252. Josephson K, DiGiacomo R, Indelicato SR, Iyo AH, Nagabhushan TL, et al. 2000. Design and analysis of an engineered human interleukin-10 monomer. J. Biol. Chem. 275:13552-57
253. Syto R, Murgolo NJ, Braswell EH, Mui P, Huang E, Windsor WT. 1998. Structural and biological stability of the human interleukin 10 homodimer. Biochemistry 37:16943-51
254. Zdanov A, Schalk-Hihi C, Menon S, Moore KW, Wlodawer A. 1997. Crystal structure of Epstein-Barr virus protein BCRF1, a homolog of cellular interleukin-10. J. Mol. Biol. 268:460-67
255. Jones BC, Logsdon NJ, Josephson K, Cook J, Barry PA, Walter MR. 2002. Crystal structure of human cytomegalovirus IL-10 bound to soluble human IL-10R1. Proc. Natl. Acad. Sci. USA 99:9404-9
256. Livnah O, Johnson DL, Stura EA, Farrell FX, Barbone FP, et al. 1998. An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat. Struct. Biol. 5:993-1004
257. Remy I, Wilson IA, Michnick SW. 1999. Erythropoietin receptor activation by a ligand-induced conformation change. Science 283:990-93
258. Soh J, Donnelly RJ, Kotenko S, Mariano TM, Cook JR, et al. 1994. Identification and sequence of an accessory factor required for activation of the human interferon-γ receptor. Cell 76:796-803
259. Landar A, Curry B, Parker MH, DiGiacomo R, Indelicato SR, et al. 2000. Design, characterization, and structure of a biologically active single-chain mutant of human IFN-gamma. J. Mol. Biol. 299:169-79
260. Krause CD, Lunn CA, Izotova LS, Mirochnitchenko O, Kotenko SV, et al. 2000. Studies on signaling of covalent heterodimers of interferon-γ: evidence for one-sided signaling in the active tetrameric receptor complex. J. Biol. Chem. 275:22995-3004
261. Ding Y, Qin L, Zamarin D, Kotenko SV, Pestka S, et al. 2001. Differential IL-10R1 expression plays a critical role in IL-10-mediated immune regulation. J. Immunol. 167:6884-92
262. Crepaldi L, Gasperini S, Lapinet JA, Calzetti F, Pinardi C, et al. 2001. Up-regulation of IL-10R1 expression is required to render human neutrophils fully responsive to IL-10. J. Immunol. 167:2312-22
263. Bazan JF. 1990. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA 87:6934-38
264. Bazan JF. 1990. Shared architecture of hormone binidng in type I and type II interferon receptors. Cell 61:753-54
265. Harlos K, Martin DM, O'Brien DP, Jones EY, Stuart DI, et al. 1994. Crystal structure of the extracellular region of human tissue factor. Nature 370:662-66
266. Banner DW, D'Arcy A, Chene C, Winkler FK, Guha A, et al. 1996. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 380:41-46
267. Hage T, Sebald W, Reinemer P. 1999. Crystal structure of the interleukin-4/receptor α chain complex reveals a mosaic binding interface. Cell 97:271-81
268. Roisman LC, Piehler J, Trosset JY, Scheraga HA, Schreiber G. 2001. Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking. Proc. Natl. Acad. Sci. USA 98:13231-36
269. Chill JH, Nivasch R, Levy R, Albeck S, Schreiber G, Anglister J. 2002. The human interferon receptor: NMR-based modeling, mapping of the IFN-α2 binding site, and observed ligand-induced tightening. Biochemistry 41:3575-85
270. Logsdon NJ, Jones BC, Josephson K, Cook J, Walter MR. 2002. Comparison of interleukin-22 and interleukin-10 soluble receptor complexes. J. Interferon Cytokine Res. 22:1099-112
271. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. 1997. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25:4876-82
272. Versteeg HH, Peppelenbosch MP, Spek CA. 2003. Tissue factor signal transduction in angiogenesis. Carcinogenesis 24:1009-13
273. Dumoutier L, Lejeune D, Hor S, Fickenscher H, Renauld JC. 2003. Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3, Biochem. J. 370:391-96
274. Aguet M, Dembic Z, Merlin G. 1988. Molecular cloning and expression of the human interferon-γ receptor. Cell. 55:273-80
275. Bach EA, Aguet M, Schreiber RD. 1997. The IFNγ receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15:563-91
276. Hemmi S, Bohni R, Stark G, Di Marco F, Aguet M. 1994. A novel member of the interferon receptor family complements functionality of the murine interferon γ receptor in human cells. Cell 76:803-10
277. Uze G, Lutfalla G, Gresser I. 1990. Genetic transfer of a functional human interferon α receptor into mouse cells: cloning and expression of its cDNA. Cell. 60:225-34
278. Pestka S. 1997. The interferon receptors. Semin. Oncol. 24: S9-18-S9-40
279. Ho AS, Liu Y, Khan TA, Hsu DH, Bazan JF, Moore KW. 1993. A receptor for interleukin 10 is related to interferon receptors. Prc. Natl. Acad. Sci. USA 90:11267-71
280. Lutfalla G, McInnis MG, Antonarakis SE, Uze G. 1995. Structure of the human CRFB4 gene: comparison with its IFNAR neighbor. J. Mol. Evol. 41:338-44
281. Lutfalla G, Gardiner K, Uze G. 1993. A new member of the cytokine receptor gene family maps on chromosome 21 at less than 35 kb from IFNAR. Genomics 16:366-73
282. Pestka S, Kotenko SV, Muthukumaran G, Izotova L, Cook JR, Garotta G. 1997. The interferon γ (IFN-γ) receptor: a paradigm for the multichain cytokine receptor. Cytokine Growth Factor Rev. 8:189-206
283. Senda T, Saitoh S, Mitsui Y. 1995. Refined crystal structure of recombinant murine interferon-β at 2.15 Å resolution. J. Mol. Biol. 253:187-207
284. Klaus W, Gsell B, Labhardt AM, Wipf B, Senn H. 1997. The three-dimensional high resolution structure of human interferon α-2a determined by heteronuclear NMR spectroscopy in solution. J. Mol. Biol. 274:661-75
285. Josephson K, Jones BC, Walter LJ, Di-Giacomo R, Indelicato SR, Walter MR. 2002. Non-competitive antibody neutralization of IL-10 revealed by protein engineering and x-ray crystallography. Structure 10:981-87
286. Muller YA, Ultsch MH, Kelley RF, de Vos AM. 1994. Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding site. Biochemistry 33:10864-70
287. Muller YA, Ultsch MH, de Vos AM. 1996. The crystal structure of the extracellular domain of human tissue factor refined to 1.7 Å resolution. J. Mol. Biol. 256:144-59
288. Muller YA, Kelley RF, de Vos AM. 1998. Hinge bending within the cytokine receptor superfamily revealed by the 2.4 Å crystal structure of the extracellular domain of rabbit tissue factor. Protein Sci. 7:1106-15
289. Zhang E, St Charles R, Tulinsky A. 1999. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant. J. Mol. Biol. 285:2089-104